Table 6.

Incidence of all causality treatment-emergent adverse events that occurred in ≥2 subjects in any one treatment arm in study 1^a

Adverse event	No. (%) of subjects
	Lersivirine at 1,000 mg q.d. + rifampin at 600 mg q.d. (n = 15)		Lersivirine at 1,000 mg q.d. + placebo q.d. (n = 16)
	Mild	Moderate	Mild	Moderate
Chromaturia	15 (100)	0	0	0
Dizziness	8 (53)	0	7 (44)	1 (6)
Nausea	2 (13)	1 (7)	7 (44)	0
Somnolence	1 (7)	0	2 (13)	0
Insomnia	2 (13)	0	1 (6)	0
Flatulence	0	0	3 (19)	0
Headache	1 (8)	0	1 (6)	1 (6)
Abdominal distension	0	0	2 (13)	0
Diarrhea	2 (13)	0	1 (6)	0
Lip dry	0	0	2 (12)	0

^aNo cases of severe treatment-emergent adverse events were recorded.